#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Fatty acid oxidation disorder Glycogen storage disease type V Cold type haemolytic anaemia Li-Fraumeni syndrome Growth hormone deficiency Congenital myopathy Cerebral arteriovenous malformation haemorrhagic B-cell type acute leukaemia Malignant glioma Depression Cardiac sarcoidosis Hormone-dependent prostate cancer Acquired C1 inhibitor deficiency B-cell small lymphocytic lymphoma recurrent Hereditary optic atrophy More trials…

    Learn about Rare Diseases

    Urea cycle disorder – Basic Information Richter’s syndrome – Diagnostics Congenital nephrogenic diabetes insipidus – Basic Information Factor VIII deficiency – Trials in Disease Andersen-Tawil syndrome Propionic acidaemia – Life with Disease Erdheim-Chester disease – Diagnostics Aicardi-Goutieres syndrome Hereditary ataxia – Trials in Disease Usher’s syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dabigatran Finasteride Spironolactone Gskvx000000017033 Brigatinib GSKVX000000034796 Atomoxetine TETRODOTOXIN Atl001 Ticagrelor Bcmacp03 Marstacimab Asundexian The-630 Basimglurant Mitoxantrone Hydrochloride Fitusiran Acetic Acid, Glacial Risedronate Sodium Hypromellose More therapies…

    Learn about Your Condition

    Stomatitis Cutibacterium acnes infection Pulmonary embolism Diabetes insipidus Retinitis pigmentosa Schizophreniform disorder Rectal cancer stage II Immunosuppression Epilepsy Agitation Anaplastic thyroid cancer Invasive breast carcinoma Tumour of ampulla of Vater Haemorrhage Iron deficiency anaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Fondation A De Rothschild

Fondation A De Rothschild

29 Rue Manin, Paris, 75019, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

    Recruiting

    3 1
    Investigated Diseases:
    • Generalised tonic-clonic seizure
    Investigated Drugs:
    • Azetukalner
    Austria Belgium Bulgaria Croatia Czechia France +6

  • Study on the Effects of Annual vs. Semi-Annual Ocrelizumab Infusions in Patients with Active Multiple Sclerosis After 2 Years of Initial Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    France

  • Study on ONC201 and Everolimus with Radiotherapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Other Diffuse Midline Gliomas in Children, Adolescents, and Adults

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • 2,4,6,7,8,9-Hexahydro-4-((2-Methylphenyl)Methyl)-7-(Phenylmethyl)Imidazo(1,2-A)Pyrido(3,4-E)Pyrimidin-5(1H)-One
    • Everolimus
    Austria Belgium Czechia Denmark Finland France +5

  • Study on Donepezil Versus Non-drug Treatment for Patients with Alzheimer’s Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Donepezil
    France

  • Study on Avoiding Anticoagulation with Apixaban for Patients with Intracerebral Hemorrhage

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Cerebral haemorrhage
    Investigated Drugs:
    • Apixaban
    France

  • A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Age-related macular degeneration
    Investigated Drugs:
    • Fluorescein Sodium
    • Aflibercept
    Austria Croatia Czechia Denmark France Hungary +4

  • Long‑Term Safety and Tolerability of Probenecid (PTI5803) as Adjunctive Therapy in Patients ≥14 Years with Drug‑Resistant Focal Epilepsy due to Focal Cortical Dysplasia

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Epilepsy
    France

  • Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Ischaemic stroke
    Investigated Drugs:
    • Tenecteplase
    France

  • Phase 3 Open‑Label Extension Study of Long‑Term Safety and Efficacy of Rozanolixizumab in Adults with Ocular Myasthenia Gravis

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Ocular myasthenia
    Investigated Drugs:
    • Rozanolixizumab
    France Germany Greece Hungary Italy Poland +1

  • Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

    Not yet recruiting

    3 1
    Belgium France Germany Italy Spain
Previous Page
1 2 3 4 5 6 … 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!